Risks Rising for Healthcare Sector As Harsh Political Rhetoric Returns Trump returns to drug pricing attacks. Healthcare sector lags. Opioid crisis blames drug distribution companies for easy access. Sector on hold awaiting Q3 earnings: XLV down 0.44% today near its 52 week high. The early rally in biotech and drug stocks reversed on the 10 […]
Speculation in Small Cap Biotech Picks Up-A Boon for Diligent Traders ETF Buying Is Driving All Small Cap and MicroCap Stocks Higher A Healthy Small Cap Rotation for Now: Reflation Trade ? Biotech stocks are rallying ahead of the expected strong seasonality in the November-January time frame. A rotation into smaller caps is leading the […]
Biotech Stocks Break Through to 2017 Highs in a Broad Rally NASDAQ up 066%, IBB up 0.92%, XBI up 0.8% The XBI is up 3.17% this week, 46% YTD, compared to only 1.1% WTD for the IBB. The breakthrough gains for the XBI can be attributed to strong performance of top ten holdings that are […]
Markets Stable After Major FED Meeting: On Course for Gradual QT(Quantitative Tightening) FED to shrink assets by year end, 2 yr TSY up to 1.43% yield. Biotech stocks up slightly near September Top IBB $332.75, XBI $85.17. Large caps green: growth and value perceived: ABBV and REGN are leaders over 1%. Mid-cap big mover Alnylam […]
M&A Boosts Biotech Stocks For Third Day Gilead Sciences (GILD) and bluebird bio (BLUE) Both Soar Today Biotech Sector Back to 2017 Highs The prospect of more M&A boosts biotech stocks for a third day this week. The large cap based IBB was up 1.87% today and 6.48% over five days to $323.76 approaching its […]
Update–11:30am Aug 28 Green Screen in Biotech Especially CAR-T Plays (BLUE,CLLS,JUNO) NASDAQ up a tad 0.21%, but broad market flattish. Biotech Deal Boosts ETFs: FBT up 2.71%, IBB up 1.53%, XBI up 2.53%. Bellwether Celgene (CELG) up 1.4%. AMGN up 1.24%, BIIB up 2.67%, GILD up 1.57%. Mid-Caps: ICPT up 1.98%, INCY up 0.9%, JUNO […]
Rayno Large Cap Biopharma Earnings Summary 8/1/17 Biotech Stocks Hit Highs in Mid-July up 18%, 30% on XBI (Click on “urls” below for Company Press Release) All the large cap biopharmaceutical earnings have come in except Regeneron (REGN) which will report on August 3. Stocks were broadly higher in July after financial reports, however we suggested […]
Update-2 7/31 After Close: Biotechs Remain Weak But No Sell Signal As we track the XBI over the past 5 days we are about 3.2% off highs from $82 down to $78.17. Although the XBI has been our top ETF pick since January 2017 we recently put new buys on hold and suggested last week […]
Update-1… JY 19…Biotech and Healthcare Stocks Continue to Rally IBB breaks through top to $322.92 up 21.68% YTD; XBI up 1.34% today 35.4% YTD; XLV up 17.6% YTD. Rayno Life Science top winners YTD: ABBV up 18.19%, AMGN up 22.6%, BLUE up 55% YTD, FMI up 114.7%, RHHBY up 12.86%. All beating the S&P. BMY […]
Big Biotech Gains for Stocks in First Half Rayno Life Science Picks Top Winners YTD: Foundation Medicine (FMI) up 124.6%, bluebird bio (BLUE) up 70.26%, XBI up 20.9%. Large cap winners since inception: Abbvie (ABBV) and Roche ADR (RHHBY). 6/27 Take some profits on XBI at $78. XBI is our top ETF pick. XLV SPDR […]
PO Box 3701
Manhattan Beach CA 90266
(310) 871-1231
rod@rayno.com
Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.